Long oppertunity HALO Halozyme Therapeutics Inc (Mid-Term)
Company showing a great increase in fundamental strength and many good highlights
Fundamental
- Expect to strongly grow 50-70% Cashflow per share.
- Expect to 20% grow in one year.
- Turnover is rapidly growing.
Fundamental
- Expect to strongly grow 50-70% Cashflow per share.
- Expect to 20% grow in one year.
- Turnover is rapidly growing.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.